Small Business: Cell and Molecular Biology – MCST (15)
This special emphasis panel reviews small business applications in the general area of cell biology, molecular biology, and genetics. Emphasis is on technology developments in cellular cultures, assays, measurements, and imaging, or technology developments in genetic assays, diagnostics, sequencing, and engineering.
Review Dates
Topics
- Novel cell-based technologies for monitoring molecular interactions and/or cellular activity and high-throughput/high-content assay design
- Development of new technologies for cell culture, separations, and sorting, including flow cytometry and stem cells
- Development of new technologies for transgenic systems
- Development of new technologies and assays for genetics, genomics, and functional genomics
- Cryopreservation/vitrification of cells
Shared Interests and Overlaps
There are shared interests with Drug Discovery and Development (MBBC (10)). Applications using cells for drug discovery or pharmacological screenings may be assigned to BCMB (10). Applications developing new cell-based technologies and assays may be assigned to MCST (15).
There are shared interests with Biomaterials, Delivery, and Nanotechnology (BBBT (10)). Applications integrating cells into biomaterial constructs and/or studying the integration of biomaterials into cellular environments may be assigned to BBBT (10). Applications developing new cell-based technologies and assays may be assigned to MCST (15). Tissue engineering and microphysiological systems (e.g. organ-on-a-chip) applications are the domain of BBBT (10).
There are shared interests with Bioanalytical Chemistry, Chemistry, Biophysics, and Assay Development (MCST (10)). Applications developing assays or technologies that are not cell-based may be assigned to MCST (10). Applications developing assays with a cell component may be assigned to MCST (15).
There are shared interests with Instrumentation, Environmental, and Occupational Safety (MCST (12)). Applications developing technologies with a significant engineering component may be assigned to MCST (12), whereas applications having a dominant cell biology component may be assigned to MCST (15).
In the area of cryopreservation, there are shared interests with organ- and clinically-based small business panels. Applications developing cryopreservation strategies for organs and large tissues may be assigned to the relevant organ or clinically-based small business panel, whereas applications developing cryopreservation of cells may be assigned to MCST (15).
There are shared interests between the small business panels in the Molecular and Cellular Sciences and Technologies Review Branch (MCST 10, 12, 14, and 15) and Small Business: Clinical Care and Health Interventions (CCHI 10) in the development of devices and technologies. Applications are reviewed in MCST if they are related to disease-agnostic diagnostic technologies (MCST-10) classification systems (MCST-14), sensors and imaging devices (MCST-12) and genomics technologies (MCST-15). Applications are reviewed in CCHI 10 if they involve the use of biomedical engineering to influence health risks and behaviors.
